Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.64 |
| ▸ | MMP3 | P08254 | 12/20 | 0.64 |
| ▸ | MMP1 | P03956 | 3/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | MMP14 | P50281 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 2/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989235 | 1.00 | MMP2 (0.64) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL17510919 | 1.00 | MMP2 (0.64) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL16156173 | 1.00 | MMP2 (0.64) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL22284089 | 1.00 | MMP2 (0.64) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6850568 | 1.00 | MMP2 (0.64) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL24252160 | 1.00 | MMP2 (0.64) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL16147773 | 0.94 | MMP2 (0.57) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL16147770 | 0.94 | MMP2 (0.57) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL16148632 | 0.91 | MMP2 (0.52) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL16148630 | 0.91 | MMP2 (0.52) | MMP2MMP3MMP1MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472391-B2 | Methods and compositions using ADAM10 inhibitors to treat bacterial infections | THE UNIVERSITY OF CHICAGO (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2014165746-A1 | METHODS AND COMPOSITIONS USING ADAM10 INHIBITORS TO TREAT BACTERIAL INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472391-B2 | Methods and compositions using ADAM10 inhibitors to treat bacterial infections | ADAM10, ADAM17, ADAM9 | MMP2 35/4885MMP3 38/4885MMP1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.